



MSCO News

August 2019



*Massachusetts
Society of Clinical
Oncologists*

*Dedicated to
improving cancer
care and treatment*

MSCO's Annual Meeting

November 14,, 2019

MSCO is looking forward to Dr. Priscilla Brastianos, MD presenting "Shifting Paradigms in Primary and Metastatic Brain Tumors" at its Annual Meeting on Thursday, November 14th at the Newton Marriott. Members can register for free. Members can also invite a colleague for free. Learn more and register [HERE](#).



**Shifting Paradigms in Primary and
Metastatic Brain Tumors: Unleashing
the Power of Genomics to Clinical Care**

Priscilla K. Brastianos, MD

Director, CNS Metastasis Center
Divisions of Hematology/Oncology and Neuro-Oncology
Departments of Medicine and Neurology
Massachusetts General Hospital/Harvard Medical School

President's Corner

Welcome to the first issuing of the President's Corner! As I have thought about this column and what it may include, many thoughts have entered and exited my head. My first thought was to have a small area of MSCO's newsletter dedicated to topics relevant to MSCO's advocacy efforts to improve care for our patients in the Commonwealth. Then, I thought maybe I should keep it light and talk about subjects other than medicine that may rejuvenate oncologists as they care for their patients.

[Press here to continue reading President's Corner.](#)



- Colleague to Colleague -

MSCO's Oncologist of the Year

MSCO is pleased to announce that Dr. Therese Mulvey will be recognized as Oncologist of the Year at its Annual Meeting on Thursday, November 14th. [Read full press release.](#)

ASH Meeting on Hematologic Malignancies

September 6-7, 2019

Featuring the top experts in the field, comprehensive clinical content, and the opportunity to interact with colleagues in an intimate, small-group setting with no competing sessions. [Learn more.](#)

Head & Neck Cancer Symposium

October 11, 2019

Hosted by BU and DFCI.

MSCO Poster Competition

MSCO invites fellows and residents to submit abstracts for its poster competition on Thursday, November 14. More details are [HERE](#).

MSCO's Audesse Award Recipient- Team Cork

MSCO is pleased to announce that this year's recipient of the Audesse Award is **Team Cork**. [Read the full press release](#) or visit Team Cork's website [HERE](#).



Abstracts due by Sept. 6th.
Click [HERE](#) for details.

Now **CONNECT** with MSCO
on **LinkedIN**.

For weekly updates about
MSCO and the latest in
oncology and cancer care in
Massachusetts, you can now
connect with MSCO on
LinkedIn.



Join MSCO for FREE!

Encourage your colleagues to
Join! Membership is free. If
100% of all the oncologists in
your practice become MSCO
members, the practice will be
highlighted on MSCO's
website, its newsletter, and
formally recognized at MSCO's
Annual Meeting. It is easy to
join [online](#) or
email nstrunk@mms.org.

MSCO on Facebook

The Facebook logo, consisting of a blue rounded rectangle with the word 'facebook' in white lowercase letters.

- FDA Approvals & Updates -

The U.S. Food and Drug
Administration
approved **pembrolizumab (Keytruda
; Merck)** for patients with recurrent,
locally advanced or metastatic,
squamous cell carcinoma of the
esophagus (ESCC) whose tumors
express RD-L1 (Combined Positive
Score [CPS] ≥ 10), as determined by

The U.S. Food and Drug
Administration
approved **daratumumab (Darzalex;
Janssen)** in combination with
lenalidomide and dexamethasone for
patients with newly diagnosed
multiple myeloma who are ineligible
for autologous stem cell
transplant. [Read full press release.](#)

an FDA-approved test, with disease progression after one or more prior lines of systematic therapy. [Read full press release.](#)

The U.S. Food and Drug Administration granted accelerated approval to **pembrolizumab (Keytruda; Merck)** for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. [Read full press release.](#)

The U.S. Food and Drug Administration approved **pembrolizumab (Keytruda; Merck)** for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). [Read full press release.](#)

The U.S. Food and Drug Administration approved **lenalidomide (Revlimid; Celgene)** in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). [Read full press release.](#)

The U.S. Food and Drug Administration granted accelerated approval to **polatuzumab vedotin-piiq (Polivy; Genentech)**, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. [Read full press release.](#)

The U.S. Food and Drug Administration approved the addition of overall survival data in labeling for **gilteritinib (Xospata; Astellas)** indicated for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. [Read full press release.](#)

The U.S. Food and Drug Administration approved **pembrolizumab (Keytruda; Merck)** for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).

The U.S. Food and Drug Administration

The U.S. Food and Drug Administration approved **alpelisib (Piqray; Novartis)** in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. [Read full press release.](#)

The U.S. Food and Drug Administration approved **fedratinib (Inrebic; Impact Biomedicines-Celgene)** for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). [Read full press release.](#)

approved **venetoclax (Venclexta; AbbVie and Genentech)** for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [Read full press release.](#)

The U.S. Food and Drug Administration approved **ruxolitinib (Jakafi; Incyte)** for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. [Read full press release.](#)